EP1670486A4 - Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof - Google Patents

Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof

Info

Publication number
EP1670486A4
EP1670486A4 EP04789289A EP04789289A EP1670486A4 EP 1670486 A4 EP1670486 A4 EP 1670486A4 EP 04789289 A EP04789289 A EP 04789289A EP 04789289 A EP04789289 A EP 04789289A EP 1670486 A4 EP1670486 A4 EP 1670486A4
Authority
EP
European Patent Office
Prior art keywords
adminisration
aminosugar
mammal
treatment
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04789289A
Other languages
German (de)
French (fr)
Other versions
EP1670486A1 (en
Inventor
Youe-Kong Shue
Franklin W Okumu
Alexander R Shikhman
Martin Lotz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Optimer Pharmaceuticals LLC
Original Assignee
Scripps Research Institute
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, Optimer Pharmaceuticals LLC filed Critical Scripps Research Institute
Publication of EP1670486A1 publication Critical patent/EP1670486A1/en
Publication of EP1670486A4 publication Critical patent/EP1670486A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP04789289A 2003-10-01 2004-09-30 Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof Withdrawn EP1670486A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50771603P 2003-10-01 2003-10-01
PCT/US2004/032048 WO2005034961A1 (en) 2003-10-01 2004-09-30 Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof

Publications (2)

Publication Number Publication Date
EP1670486A1 EP1670486A1 (en) 2006-06-21
EP1670486A4 true EP1670486A4 (en) 2009-04-01

Family

ID=34434891

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04789289A Withdrawn EP1670486A4 (en) 2003-10-01 2004-09-30 Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof

Country Status (5)

Country Link
EP (1) EP1670486A4 (en)
JP (1) JP2007507516A (en)
CN (1) CN1909911A (en)
CA (1) CA2540586A1 (en)
WO (1) WO2005034961A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713485A4 (en) * 2004-01-20 2007-09-19 Optimer Pharmaceuticals Inc Treatment of degenerative cartilage conditions in a mammal with glycosidase inhibitors
CA2731201C (en) * 2008-07-18 2018-10-16 Genis Ehf. Composition for treating autoimmune disorders
KR101098581B1 (en) 2009-01-09 2011-12-26 서울대학교산학협력단 Composition for Improving Inflammatory Disorder Using ABH Antigen
JP2013543898A (en) * 2010-11-24 2013-12-09 デュレクト コーポレイション Biodegradable drug delivery composition
CN102614111B (en) * 2012-04-05 2013-11-06 苏州豫源生物医药有限公司 Glucosamine gel and preparation method thereof
CN105884720A (en) * 2016-04-23 2016-08-24 陈斌 Buspirone hydrochloride pharmaceutical composition and medical application thereof
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN112169713A (en) * 2020-09-09 2021-01-05 江南大学 N-alkyl lactosamine surfactant micromolecule alcogel and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379753A1 (en) * 1989-01-26 1990-08-01 Steigerwald Arzneimittelwerk Gmbh N-acetyl glucosamine preparations for buccal use
WO1997021434A1 (en) * 1995-12-11 1997-06-19 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
WO1998025631A1 (en) * 1996-12-13 1998-06-18 Lescarden, Inc. Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
WO2002078445A1 (en) * 2001-03-29 2002-10-10 The Scripps Research Institute Formulations comprising entrapped active ingredients and uses thereof
WO2003026677A1 (en) * 2001-09-26 2003-04-03 Primex Ehf. Pharmaceutical composition comprising chito-oligomers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM666894A0 (en) * 1994-07-07 1994-07-28 University Of Melbourne, The Diagnostic methods and compositions
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6514522B2 (en) * 1998-04-08 2003-02-04 Chondros, Inc. Polymer constructs
JP2002515488A (en) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Carboxamide compounds, compositions, and methods for inhibiting PARP activity
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US6662805B2 (en) * 1999-03-24 2003-12-16 The Johns Hopkins University Method for composite cell-based implants
MXPA01011542A (en) * 2001-11-13 2003-05-22 Alcon Inc Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
JP2003225093A (en) * 2001-11-30 2003-08-12 Sumitomo Pharmaceut Co Ltd Marker for cartilage disorder and use thereof
BR0214610A (en) * 2001-11-30 2004-09-14 Pfizer Controlled release polymeric compositions of bone growth promoting compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379753A1 (en) * 1989-01-26 1990-08-01 Steigerwald Arzneimittelwerk Gmbh N-acetyl glucosamine preparations for buccal use
WO1997021434A1 (en) * 1995-12-11 1997-06-19 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
WO1998025631A1 (en) * 1996-12-13 1998-06-18 Lescarden, Inc. Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
US6117851A (en) * 1996-12-13 2000-09-12 Lescarden Inc. Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
WO2002078445A1 (en) * 2001-03-29 2002-10-10 The Scripps Research Institute Formulations comprising entrapped active ingredients and uses thereof
WO2003026677A1 (en) * 2001-09-26 2003-04-03 Primex Ehf. Pharmaceutical composition comprising chito-oligomers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREILING H ET AL: "DIE HEMMUNG LYSOSOMALER ENZYME DURCH EIN GLYKOSAMINOGLYKANPOLYSULFAT ZUR THERAPIE CHRONISCHER GELENKERKRANKUNGEN MIT ANTIDEGENERATIV WIRKSAMEN VERDINGUNGEN; EIN BEITRAG ZUR BIOCHEMIE", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 23, no. 4, 1 January 1973 (1973-01-01), pages 593 - 597, XP000990352, ISSN: 0004-4172 *
LIU J ET AL: "Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 8, no. 7, 1 January 2001 (2001-01-01), pages 701 - 711, XP002444424, ISSN: 1074-5521 *
See also references of WO2005034961A1 *
SHIKHMAN A R ET AL: "N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 5155 - 5160, XP002505181, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
JP2007507516A (en) 2007-03-29
CA2540586A1 (en) 2005-04-21
WO2005034961A1 (en) 2005-04-21
EP1670486A1 (en) 2006-06-21
CN1909911A (en) 2007-02-07

Similar Documents

Publication Publication Date Title
ZA200600716B (en) Improvements in and to processes
GB2406925B (en) Facilitating and authenticating transactions
HK1077274A1 (en) Closed capsule with opening mean and use thereof
EP1543034A4 (en) Treatment and prophylaxis with 4-1bb-binding agents
GB0212551D0 (en) Improvements in and relating to optical devices
IL172316A0 (en) Novel compounds and their use in therapy
GB2407272B (en) Improvements in and relating to peripheral neurostimulation
EP1670486A4 (en) Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof
AU2003207824A8 (en) K-type polarizer and preparation thereof
GB0303663D0 (en) Assays and medical treatments
SG110107A1 (en) Compound and use in treatment
EP1691779A4 (en) Treatment of a condition in a mammal with administration of compounds and methods of use thereof
GB2409518B (en) Improvements in and relating to investigations
GB2388995B (en) Improvements in and relating to alarms
GB2405878B (en) Improvements in and relating to weatherboarding
EP1531905A4 (en) Metallothionein based neuronal therapeutic and therapeutic methods
GB0202953D0 (en) Improvements in gates and railings
GB0325598D0 (en) Compound and use in treatment
GB0306473D0 (en) Improvements in and relating to connectors
GB0416876D0 (en) Compound and use in treatment
GB2428791B (en) Improvements in and relating to investigations
AU2003902089A0 (en) Improvements in mechanisms and devices
GB0329506D0 (en) Methods and therapeutic treatments
GB0329539D0 (en) Improvements in and relating to investigations
GB0207292D0 (en) Improvements in and relating to valves

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OPTIMER PHARMACEUTICALS

Owner name: THE SCRIPPS RESEARCH INSTITUTE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHUE, YOUE-KONG

Inventor name: LOTZ, MARTIN

Inventor name: OKUMU, FRANKLIN, W.

Inventor name: SHIKHMAN, ALEXANDER, R.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE SCRIPPS RESEARCH INSTITUTE

Owner name: OPTIMER PHARMACEUTICALS, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20090226BHEP

Ipc: A61K 31/70 20060101AFI20050425BHEP

17Q First examination report despatched

Effective date: 20091013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101122